Minimal Clinically Important Difference (MCID) of clinical endpoints in AIT
Minimal Clinically Important Difference (MCID) of clinical endpoints in AIT
This Task-Force initiative evaluates an important methodological question on trial-design methodology in AIT, the;”minimally clinical important difference (MCID)” of endpoints for assessing the clinical efficacy of AIT in trials.
IG: Allergen Immunotherapy
Chair: Oliver Pfaar
Secretary: Durham